These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6467792)

  • 1. Serum disopyramide concentrations and suppression of ventricular premature contractions.
    Ueda CT; Dzindzio BS; Vosik WM
    Clin Pharmacol Ther; 1984 Sep; 36(3):326-36. PubMed ID: 6467792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
    Capparelli EV; DiPersio DM; Zhao H; Kluger J; Chow MS
    J Clin Pharmacol; 1988 Apr; 28(4):306-11. PubMed ID: 3392228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous disopyramide: safety and efficacy of a new dosage regimen.
    Reddy CP; Benes J; Beck B
    Clin Pharmacol Ther; 1984 May; 35(5):610-6. PubMed ID: 6713772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mexiletine and disopyramide suppress ventricular premature contractions (VPC) irrespective of the relationship between the VPC and the underlying heart rate.
    Saikawa T; Nakagawa M; Takahashi N; Ishida S; Fujino T; Ito M; Shimoyama N; Hara M; Yonemochi H; Maeda T
    Jpn Heart J; 1992 Sep; 33(5):665-78. PubMed ID: 1283888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1979; 205(5):417-23. PubMed ID: 443082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute oral antiarrhythmic testing with disopyramide.
    García-Barreto D; Toruncha A; Gonzalez-Gomez A; Llerena L; Groning E; Hernandez-Cañero A
    Clin Cardiol; 1981; 4(6):330-5. PubMed ID: 7326884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of propafenone versus disopyramide for complex premature ventricular contractions. Evaluation with long-term monitoring.
    Naccarella F; Palmieri M; del Corso P; Lombardi G; Bracchetti D
    Arzneimittelforschung; 1982; 32(5):547-50. PubMed ID: 7201833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
    Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
    Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias.
    Arif M; Laidlaw JC; Oshrain C; Willis PW; Nissen CH; McDermott DJ; Smith WS; Karim A; Wilson RR
    Angiology; 1983 Jun; 34(6):393-400. PubMed ID: 6408949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
    Lima JJ; Haughey DB; Leier CV
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical pharmacology of disopyramide].
    Rewerski W; Dorociak A; Walczak F; Dobiasz A
    Pol Tyg Lek; 1980 Jul; 35(29):1109-12. PubMed ID: 7001399
    [No Abstract]   [Full Text] [Related]  

  • 16. Measurement of plasma disopyramide as a guide to paediatric use.
    Baker EJ; Hayler AM; Curry PV; Tynan M; Holt DW
    Int J Cardiol; 1986 Jan; 10(1):65-9. PubMed ID: 3943929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiarrhythmic action of disopyramide: a study of plasma levels].
    Page A; Pic A; Besse P
    Arch Mal Coeur Vaiss; 1979 Jul; 72(7):774-80. PubMed ID: 117775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
    Taylor EH; Pappas AA
    Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias.
    Chiba K; Koike K; Nakamoto M; Echizen H; Ishizawa A; Ishizaki T
    Ther Drug Monit; 1992 Apr; 14(2):112-8. PubMed ID: 1585394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.